Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin

Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin

A central treatment resistance mechanism in solid tumors is the maintenance of epithelial junctions between malignant cells that prevent drug penetration into the tumor. We have developed a small recombinant protein (JO-1) that triggers the transient opening of intercellular junctions and thus incre...

Full description

Bibliographic Details
Main Authors: Maximilian Richter, Roma Yumul, Hongjie Wang, Kamola Saydaminova, Martin Ho, Drew May, Audrey Baldessari, Michael Gough, Charles Drescher, Nicole Urban, Steve Roffler, Chloé Zubieta, Darrick Carter, Pascal Fender, André Lieber
Format: Article
Language:English
Published: Elsevier 2015-01-01
Series:Molecular Therapy: Methods & Clinical Development
Online Access:http://www.sciencedirect.com/science/article/pii/S2329050116300171

Internet

http://www.sciencedirect.com/science/article/pii/S2329050116300171

Similar Items